Co-Diagnostics (LTS:0A50) Cyclically Adjusted Revenue per Share: $30.28 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A50 Co-Diagnostics Inc LTS:0A50
63 GF Score
Price $1.55
GF Value $2.17
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Co-Diagnostics Cyclically Adjusted Revenue per Share?

Co-Diagnostics LTS:0A50 +1.97% 63 Cyclically Adjusted Revenue per Share is $30.28 as of Mar. 2026. GuruFocus rates LTS:0A50 with a GF Score™ of 63/100 and a GF Value™ of $2.17 (Modestly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Co-Diagnostics's adjusted revenue per share for the three months ended in Mar. 2026 was $0.065. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $30.28 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-04), Co-Diagnostics's current stock price is $1.55. Co-Diagnostics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $30.28. Co-Diagnostics's Cyclically Adjusted PS Ratio of today is 0.05.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Co-Diagnostics was 0.47. The lowest was 0.04. And the median was 0.10.


Co-Diagnostics  (LTS:0A50) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Co-Diagnostics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.55/30.28
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Co-Diagnostics was 0.47. The lowest was 0.04. And the median was 0.10.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Co-Diagnostics Cyclically Adjusted Revenue per Share Related Terms


Co-Diagnostics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Co-Diagnostics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Co-Diagnostics Cyclically Adjusted Revenue per Share Chart

Co-Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 30.01

Co-Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 29.31 30.01 30.28

LTS:0A50 vs HSCS, NVNO, SINT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Co-Diagnostics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Co-Diagnostics Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Co-Diagnostics's Cyclically Adjusted PS Ratio falls into.


LTS:0A50
63GF Score
Co-Diagnostics Inc LTS:0A50
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Co-Diagnostics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Co-Diagnostics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.065/330.2130*330.2130
=0.065

Current CPI (Mar. 2026) = 330.2130.

Co-Diagnostics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.000 241.432 0.000
201703 0.000 243.801 0.000
201706 0.005 244.955 0.007
201709 0.008 246.819 0.011
201712 0.007 246.524 0.009
201803 0.024 249.554 0.032
201806 0.024 251.989 0.031
201809 0.024 252.439 0.031
201812 0.026 251.233 0.034
201903 0.006 254.202 0.008
201906 0.109 256.143 0.141
201909 0.071 256.759 0.091
201912 0.197 256.974 0.253
202003 2.035 258.115 2.603
202006 24.733 257.797 31.681
202009 22.106 260.280 28.046
202012 27.956 260.474 35.441
202103 20.025 264.877 24.964
202106 27.606 271.696 33.552
202109 30.161 274.310 36.308
202112 20.401 278.802 24.163
202203 19.619 287.504 22.533
202206 4.642 296.311 5.173
202209 4.879 296.808 5.428
202212 1.421 296.797 1.581
202303 0.612 301.836 0.670
202306 0.204 305.109 0.221
202309 2.510 307.789 2.693
202312 3.620 306.746 3.897
202403 0.254 312.332 0.269
202406 2.646 314.175 2.781
202409 0.631 315.301 0.661
202412 0.145 315.605 0.152
202503 0.047 319.799 0.049
202506 0.148 322.561 0.152
202509 0.115 324.800 0.117
202512 0.140 324.054 0.143
202603 0.065 330.213 0.065

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $30.28 mean?
Co-Diagnostics (LTS:0A50) has a Cyclically Adjusted Revenue per Share of $30.28 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Co-Diagnostics and its competitors.
Is Co-Diagnostics' Cyclically Adjusted Revenue per Share too high?
Co-Diagnostics' current Cyclically Adjusted Revenue per Share is $30.28. Overall, Co-Diagnostics has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' Cyclically Adjusted Revenue per Share compare to HSCS and NVNO?
Co-Diagnostics' Cyclically Adjusted Revenue per Share of $30.28 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Co-Diagnostics and its competitors. Co-Diagnostics's current Cyclically Adjusted Revenue per Share is $30.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Co-Diagnostics (LTS:0A50) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.17, compared to a current price of $1.55 — trading 28.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $30.28. Co-Diagnostics' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Co-Diagnostics (LTS:0A50), the current Cyclically Adjusted Revenue per Share is $30.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Co-Diagnostics (LTS:0A50) Overvalued in 2026?

Based on GuruFocus' analysis, Co-Diagnostics stock appears to be undervalued. The current stock price of $1.55 is trading 28.6% below its estimated GF Value™ of $2.17. GuruFocus considers Co-Diagnostics to be Modestly Undervalued.

Key valuation signals for LTS:0A50:

  • Cyclically Adjusted Revenue per Share: $30.28
  • GF Value™: $2.17 vs. price of $1.55 (28.6% below fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the LTS:0A50 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Co-Diagnostics Business Description

Other Exchanges CODX:USA
Address 2401 S. Foothill Drive, Suite D, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
63GF Score

Get the complete analysis for LTS:0A50

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price
$2.17
GF Value